Therini Bio, Inc.

Therini Bio, Inc. is a clinical-stage biotechnology company focused on developing fibrin-targeting immunotherapies to address chronic neuroinflammation and neuronal damage associat

ed with severe neurological and retinal diseases, including Alzheimer’s Disease and Diabetic Macular Edema (DME). Founded in 2016 and headquartered in South San Francisco, California, Therini Bio is a private company that operates in the Drug Discovery and Biotechnology sectors. The company’s lead product candidate, THN391, is a selective monoclonal antibody designed to block fibrin-driven immune activation without impairing coagulation. Therini Bio's innovative approach targets toxic fibrin deposits, aiming to halt neuroinflammation and protect the nervous system. Their pipeline includes potential first-in-class immunotherapies applicable to a range of inflammatory diseases, with a focus on conditions where neuroinflammation is a key factor. The company has raised over $100 million in funding from notable investors, including Lilly and Sanofi, to support its mission of improving patient outcomes in neurodegenerative and retinal diseases.